In the last trading session, 1.62 million Marinus Pharmaceuticals Inc (NASDAQ:MRNS) shares changed hands as the company’s beta touched 1.12. With the company’s per share price at $1.51 changed hands at $0.06 or 4.14% during last session, the market valuation stood at $82.51M. MRNS’s last price was a discount, traded about -645.7% off its 52-week high of $11.26. The share price had its 52-week low at $1.11, which suggests the last value was 26.49% up since then. When we look at Marinus Pharmaceuticals Inc’s average trading volume, we note the 3-month average coming to 1.84 million.
Marinus Pharmaceuticals Inc (NASDAQ:MRNS) trade information
Instantly MRNS was in green as seen at the end of in last trading. With action 7.47%, the performance over the past five days has been green. The jump to weekly highs of 1.6500 added 4.14% to the stock’s daily price. The company’s shares are showing year-to-date downside of -86.11%, with the 5-day performance at 7.47% in the green. However, in the 30-day time frame, Marinus Pharmaceuticals Inc (NASDAQ:MRNS) is -82.60% down.
Marinus Pharmaceuticals Inc (MRNS) estimates and forecasts
Data shows that the Marinus Pharmaceuticals Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -77.22% over the past 6 months, a 15.21% in annual growth rate that is considerably higher than the industry average of 11.70%. Year-over-year growth is forecast to reach 31.80% up from the last financial year.
Consensus estimates given by 11 financial analysts project the company’s revenue in the current quarter to hit an average of 9.12M. 11 analysts are of the opinion that Marinus Pharmaceuticals Inc’s revenue for the current quarter will be 9.59M. The company’s revenue for the corresponding quarters a year ago was 10.38M and 6.08M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -12.10%. The estimates for the next quarter sales put growth at 57.70%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 6.04%. The 2024 estimates are for Marinus Pharmaceuticals Inc earnings to increase by 16.53%, but the outlook for the next 5-year period is at 20.00% per year.
MRNS Dividends
Marinus Pharmaceuticals Inc is expected to release its next quarterly earnings report in June.
